CIPO Patents = 2

EPO Patents = 1

Forward Citations = 199

Loading Chart...

6 inventors (with patents filed for the assignee):

Nathan Bryson (6 out of 14 patents)

Anthony John Giovinazzo (6 out of 15 patents)

Scott David Barnhart (4 out of 26 patents)

4. Michael Clinton Koons (4 out of 8 patents)

5. David Bruce Hedden (2 out of 12 patents)

6. Marc L De Somer (2 out of 7 patents)

7. Nathan John Bryson (0 patent)

8. Marc L De Somer (0 patent)

6 patents: Sort by Forward Citations

1. 9427412 - Sublingual films (2016-08-30),

2. 9326981 - Sublingual apomorphine (2016-05-03),

3. 9283219 - Sublingual films (2016-03-15),

4. 9044475 - Sublingual apomorphine (2015-06-02),

5. 8846074 - Sublingual films (2014-09-30),

6. 8414922 - Sublingual films (2013-04-09),

Cynapsus Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for Parkinson's disease. Their lead product candidate, APL-130277, is a sublingual film of apomorphine for the treatment of off episodes in Parkinson's disease patients. The company is committed to improving the lives of individuals living with neurological disorders through advanced drug development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

6 Patents

#217 in Toronto

#2,334 in Canada

Toronto, Canada

Cynapsus Therapeutics, Inc.

Forward Citations = 199

6 inventors:

Nathan Bryson (6 out of 14 patents)

Anthony John Giovinazzo (6 out of 15 patents)

Scott David Barnhart (4 out of 26 patents)

4. Michael Clinton Koons (4 out of 8 patents)

5. David Bruce Hedden (2 out of 12 patents)

Please report any incorrect information to support@idiyas.com

2 patents (CIPO):

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com